HFX AdaptivAI combines insights from over 100,000 patients and more than 100 million data points¹ and leverages artificial intelligence (AI) to deliver responsive and personalized pain relief in real ...

Data Published in Journal of Neurosurgery: Spine Highlight Lasting Pain Relief, Enhanced Function, Quality of Life, and Reduced Opioid Dependency with High-Frequency SCS Therapy The published 24-month ...

HFX iQ is the first and only spinal cord stimulation (SCS) system integrating high-frequency SCS landmark evidence with cloud data insights, leading the way for personalized, data-driven patient care* ...

Nevro yesterday announced that the FDA has granted approval for a study evaluating its high-frequency spinal cord stimulation system for the treatment of chronic pain. The device company’s Senza ...

REDWOOD CITY, Calif., Nov. 12, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic ...

Experts in diabetes, pain and health services from the Worldwide Initiative for Diabetes Education recommend spinal cord stimulation when symptoms aren't responsive to first- or second-line therapies ...

New 18-month data for a 10-kHz implanted spinal cord stimulation device (Nevro) shows continued relief of painful diabetic neuropathy symptoms in patients refractory to conventional medical therapy.

Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its neuromodulation platforms for treating chronic pain. The all-cash deal comes to a ...